Document text
Principal Investigator: JAMES E Robinson
Organization: TULANE UNIVERSITY OF LOUISIANA
Fiscal Year: 2024
Award: $310,000
Funding agency: National Cancer Institute
ABSTRACT
The SARS-CoV-2 virus, the causative agent of COVID-19, has infected a reported
13,810,247 persons globally as of July 16, 2020 with a mortality rate of 4.2%. In the
State of Louisiana, over 7.3% of the 86,411 COVID-19 cases involve people living with
cancer. Treatment with convalescent serum or plasma is currently widely used in the
setting of experimental trials and ad hoc. Theoretically, convalescent plasma contains
protective antibodies that neutralizes virus and mitigates its pathogenic effects. Yet,
there remains a large gap in our understanding of the mechanisms that drive humoral
and cellular immune responses and how these responses correlate with disease course
and protection as well as the durability of those responses. Furthermore, there is a need
for serological assays that measure these responses accurately for serodiagnosis and
as correlates of immunity and protection. Without this knowledge, the true efficacy of
convalescent plasma as therapy for COVID-19 and our understanding of the humoral
immune response to SARS-CoV-2, especially in immunocompromised patients, will
remain unknown.
A central hypothesis of our proposal is that the humoral immune responses to SARS-
CoV-2 is protective in the short-term but appears to lack durability. However, a second
hypothesis is that some remnant of immunity will be retained which will prevent
recurrence of COVID19 but not necessarily re-infection. The overall mission of the
Tulane University Convalescent Antibody and Immunity Network (TUCAIN) is to
characterize this response with respect to functionality and durability.
We will achieve these goals by studying a diverse cohort of COVID-19 survivors and
minimally sick seroconverters. Using serial blood collections, we will apply several
immunological technologies to study the evolution and durability of the immune
response over time. We will also correlate these responses to patient outcomes and
disease pathogenesis using a “big data”, systems biology approach. An approach, such
as the one we propose, will allow us to determine if COVID-19 survivors develop long-
term, antibody-based protection and we can confirm if convalescent plasma has
therapeutic potential. This research will allow us to identify new targets for medicines
and vaccines, inform personalized treatment strategies such as those required by
immunocompromised patients with cance or HIV infection, and to provide novel
immunological algorithms applicable to a wide range of human pathogens.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Administrative Supplement><Adult><Adult Human><Algorithms><Antibodies><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Big Data><BigData><Blood><Blood Plasma><Blood Plasma Cell><Blood Reticuloendothelial System><Blood Sample><Blood Serum><Blood specimen><Booster Immunization><CD4 Cells><CD4 Lymphocyte Count><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ Cell Counts><CD4+ Counts><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID crisis><COVID epidemic><COVID pandemic><COVID survivors><COVID-19><COVID-19 antibody><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 infection><COVID-19 infection survivors><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 survivors><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 virus><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CV-19><Cancers><Cas nuclease technology><Cell Count><Cell Mediated Immunology><Cell Number><Cell-Mediated Immunity><Cellular Immunity><Clinical Data><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><CoV-2><CoV2><Collection><Control Groups><Coronavirus Infectious Disease 2019><Data Set><Death Rate><Defect><Development><Diagnosis><Disease><Disorder><Enrollment><Evolution><Frequencies><Funding><General Population><General Public><Generations><Goals><HIV><HIV Infections><HTLV-III Infections><HTLV-III-LAV Infections><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Humoral Immunities><Immune><Immune memory><Immune response><Immunes><Immunity><Immunochemical Immunologic><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunologic Memory><Immunological><Immunological Memory><Immunological response><Immunologically><Immunologics><Immunosuppressed Host><Individual><Infection><Kinetics><Knowledge><LAV-HTLV-III><Link><Louisiana><Lymphadenopathy-Associated Virus><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Measures><Mediating><Medicine><Memory B Cell><Memory B-Lymphocyte><Methods><Mission><Multiple Myeloma><Pathogenesis><Pathogenicity><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Persons><Plasma><Plasma Cells><Plasma Serum><Plasma-Cell Myeloma><Plasmacytes><Population><Predisposition><RNA immunization><RNA vaccination><RNA vaccine><RNA-based vaccine><Recurrence><Recurrent><Reporting><Research><Reticuloendothelial System, Serum, Plasma><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 survivors><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Secondary Immunization><Series><Serology><Serology test><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Solid Neoplasm><Solid Tumor><Susceptibility><Systems Biology><T cell response><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T4 Cells><T4 Lymphocyte Count><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Technology><Therapeutic><Time><Universities><Vaccination><Vaccines><Variant><Variation><Viral><Viral Burden><Viral Load><Viral Load result><Virus><Virus-HIV><Visit><Vulnerable Populations><Wuhan coronavirus><adaptive immune response><adulthood><anamnestic reaction><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody-based immunity><booster dose><booster shot><booster vaccination><booster vaccine><breakthrough infection><cohort><comparable efficacy><comparative efficacy><compare efficacy><convalescent plasma><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><data integration><developmental><enroll><hCoV19><host response><human pathogen><hypoimmunity><immune competent><immune deficiency><immune system response><immunity against COVID-19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunodeficiency><immunoresponse><immunosuppressed patient><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><malignancy><mortality rate><mortality ratio><myeloma><myelomatosis><nCoV2><neoplasm/cancer><neutralizing antibody><novel><parent grant><patient oriented outcomes><patient population><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><plasmocyte><prevent><preventing><response><secondary immune response><serology assay><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><survive COVID-19><survive SARS-CoV-2><thymus derived lymphocyte><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment strategy><vaccine boost><vaccine efficacy><variants of concern><viral testing><virus testing><vulnerable group><vulnerable individual><vulnerable people>